Related Experiment Video
Updated: Jul 14, 2026
09:02
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical
Myung Geun Song1,2, Keon Wook Kang1,2,3,4
1Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Cells
|July 13, 2026
Summary
Albumin-based drug delivery shows promise for glioblastoma treatment by overcoming the blood-brain barrier. These strategies enhance drug penetration into brain tumors, offering a new avenue for managing this aggressive cancer.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Drug Delivery Systems
Background:
- Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment efficacy.
- The blood-brain barrier (BBB) and blood-tumor barrier (BTB) impede drug delivery to GBM.
- Albumin-based delivery systems offer solutions for drug solubility, systemic exposure, and targeted transport.
Purpose of the Study:
- To review albumin-based strategies for glioblastoma treatment.
- To evaluate the potential of albumin nanoparticles in overcoming BBB/BTB limitations.
- To discuss future directions for albumin-based therapies in GBM.
Main Methods:
- Review of preclinical and early clinical studies on albumin-based drug delivery for glioblastoma.
- Analysis of various albumin-based platforms including nanoparticles, photosensitizers, and pathway-directed agents.
- Examination of synergistic approaches combining albumin delivery with BBB/BTB modulation technologies.
Main Results:
- Albumin-based strategies demonstrate improved drug exposure in brain tumors in preclinical models.
- These platforms facilitate rational drug combinations and enhance synergy with BBB/BTB opening methods.
- Early clinical trials show proof of concept for regional pharmacokinetic enhancement in recurrent GBM.
Conclusions:
- Albumin-based delivery is a rational formulation strategy for glioblastoma.
- Clinical success hinges on spatial pharmacokinetic confirmation, biomarker-guided selection, and BBB/BTB modulation.
- Further research is needed to establish survival benefits in glioblastoma patients.
